[go: up one dir, main page]

WO1999038472A3 - TOPICAL VASODILATION GEL COMPOSITION AND METHODS OF USE AND PRODUCTION THEREOF - Google Patents

TOPICAL VASODILATION GEL COMPOSITION AND METHODS OF USE AND PRODUCTION THEREOF Download PDF

Info

Publication number
WO1999038472A3
WO1999038472A3 PCT/US1999/001830 US9901830W WO9938472A3 WO 1999038472 A3 WO1999038472 A3 WO 1999038472A3 US 9901830 W US9901830 W US 9901830W WO 9938472 A3 WO9938472 A3 WO 9938472A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasodilation
topical
production
methods
gel composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/001830
Other languages
French (fr)
Other versions
WO1999038472A2 (en
Inventor
Oscar Hugh Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEATRACE PHARMACEUTICALS Inc
Original Assignee
SEATRACE PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEATRACE PHARMACEUTICALS Inc filed Critical SEATRACE PHARMACEUTICALS Inc
Priority to AU24790/99A priority Critical patent/AU2479099A/en
Publication of WO1999038472A2 publication Critical patent/WO1999038472A2/en
Publication of WO1999038472A3 publication Critical patent/WO1999038472A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle composition comprenant un gel de vasodilatation s'utilisant en application topique pour la stimulation du flux sanguin, pour la visualisation des vaisseaux sanguins, pour le traitement de l'anorgasmie et pour le traitement de l'impuissance et d'autres formes d'insuffisance vasculaire; l'invention concerne également une méthode de préparation de ce gel de vasodilatation et une méthode d'utilisation de cette composition pour stimuler le flux sanguin, pour visualiser les vaisseaux sanguins, pour traiter l'anorgasmie et pour traiter l'impuissance et d'autres formes d'insuffisance vasculaire. La substance de vasodilatation préférée dans le gel de vasodilatation est la nitroglycérine.The present invention relates to a new composition comprising a vasodilation gel used in topical application for stimulation of blood flow, for visualization of blood vessels, for the treatment of anorgasmia and for the treatment of impotence and other forms of vascular insufficiency; the invention also relates to a method of preparing this vasodilation gel and a method of using this composition to stimulate blood flow, to visualize blood vessels, to treat anorgasmia and to treat impotence and others forms of vascular insufficiency. The preferred vasodilation substance in the vasodilation gel is nitroglycerin.

PCT/US1999/001830 1998-01-28 1999-01-28 Topical vasodilatory gel composition and methods of use and production Ceased WO1999038472A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24790/99A AU2479099A (en) 1998-01-28 1999-01-28 Topical vasodilatory gel composition and methods of use and production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7290498P 1998-01-28 1998-01-28
US60/072,904980128 1998-01-28

Publications (2)

Publication Number Publication Date
WO1999038472A2 WO1999038472A2 (en) 1999-08-05
WO1999038472A3 true WO1999038472A3 (en) 2000-01-20

Family

ID=22110459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001830 Ceased WO1999038472A2 (en) 1998-01-28 1999-01-28 Topical vasodilatory gel composition and methods of use and production

Country Status (2)

Country Link
AU (1) AU2479099A (en)
WO (1) WO1999038472A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6872384B1 (en) 1998-02-23 2005-03-29 Life Medical Sciences, Inc. Treatment of trauma
JP5043253B2 (en) 1999-10-21 2012-10-10 花王株式会社 Hair removal agent and external preparation
EP1318819A4 (en) * 2000-08-23 2006-03-15 Phairson Medical Inc Treatment of trauma, and other indications
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
DE202008007318U1 (en) * 2008-03-14 2008-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation with the active ingredient glycerol trinitrate
US20100184870A1 (en) * 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
EP2600837A1 (en) 2010-08-03 2013-06-12 G. Pohl-Boskamp GmbH & Co. KG Use of glyceryl trinitrate for treating hematomas
PL2678000T3 (en) 2011-02-25 2018-08-31 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
PL2668947T3 (en) 2012-05-31 2017-06-30 G. Pohl-Boskamp Gmbh & Co. Kg Induction of arteriogenesis with a nitric oxide-donor such as nitroglycerin
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
EP2878310B1 (en) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Sprayable aqueous composition comprising glyceryl trinitrate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316887A (en) * 1977-11-07 1982-02-23 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for topical application and method for preparing the same
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5571794A (en) * 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316887A (en) * 1977-11-07 1982-02-23 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for topical application and method for preparing the same
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5571794A (en) * 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite

Also Published As

Publication number Publication date
WO1999038472A2 (en) 1999-08-05
AU2479099A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
WO1999038472A3 (en) TOPICAL VASODILATION GEL COMPOSITION AND METHODS OF USE AND PRODUCTION THEREOF
Linde et al. Noncollagenous proteins of dentin. A re-examination of proteins from rat incisor dentin utilizing techniques to avoid artifacts.
HUP9801175A2 (en) Topically applied pharmaceutical composition, method of preparing it and its use
HUP9801234A2 (en) Water-based topical cream containing nitroglycerin: method of preparation and use thereof
WO2003106416A3 (en) CHEMICAL PROCESS
FI973122A0 (en) Method and compounds for magnetorelaxometric detection of analytes and their use
DE3580056D1 (en) NEW MONOCLONAL ANTIBODIES AND HYBRIDOMA CELLS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATIONS.
ATE20185T1 (en) MEANS OF PREVENTING AND TREATMENT OF LIVER AND KIDNEY DISEASES.
DE69638198D1 (en) Method and reagent for the treatment of diseases caused by the concentration of the receptor for the growth factor of the vascular endothelial cells
TNSN99145A1 (en) CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S, 2R) -3 - [[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE) AMINO] -1-BENZYLE-2- (PHOSPHONOOXY), PROPYLCARBAMATE
RO90639B (en) Process for preparing a human tissue plasminogene activator
ATE228819T1 (en) PROCESS FOR PRODUCTION OF AN AGENT FOR TEETH WHITENING AND FOR SKIN AND MUCOUS SKIN TREATMENT
ATE107850T1 (en) HEALING WATER LIPOSOMES STABILIZED IN A DNA GEL.
BE900563A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE KIDNEY DEFICIENCY.
Mäkinen Studies on oral enzymes: I. Fractionation and characterization of aminopeptidases of human saliva
FR2636968B1 (en) NUCLEIC ACID ENCODING THE HUMAN ANGIOTENSIN CONVERSION ENZYME (ACE) AND ITS APPLICATIONS, IN PARTICULAR FOR IN VITRO DIAGNOSIS OF ARTERIAL HYPERTENSION
FR2441627A1 (en) NOVEL SPIRO-POLYCYCLO-IMIDAZOLIDINEDIONES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
FR2385395A1 (en) COMPOSITION FOR INSTILLATIONS
DE60035693D1 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNOMATED DISEASES
Skalerič et al. Alpha 2‐macroglobulin in gingival fluid: correlation with alveolar bone loss in periodontal disease
BE900012A (en) NEW PEPTIDE.
ATE375389T1 (en) METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GLAUCOMA AND RELATED DISEASES
ATE178074T1 (en) PROINSULIN PEPTIDE COMPOUNDS FOR DETECTION AND TREATMENT OF TYPE I DIABETES
FR2407929A1 (en) NEW DERIVATIVES OF 4-AMINO-2- (PIPERAZIN-1-YL OR HOMOPIPERAZIN-1-YL) -QUINAZOLINE, THEIR PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
FR2393006A1 (en) UROKINASE PURIFICATION PROCESS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642